Carol Aghajanian

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 87 papers. Top paper: “MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum”.

MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

Journal of Clinical Oncology(2020)10.1200/jco.20.01164

N/A

4.6DataRank · unranked

153 citations

Rachel N. Grisham, Susana Banerjee, Elsa Kalbacher, Mansoor Raza Mirza, Ignacio Romero +25 more

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.01.025

N/A

2.5DataRank · unranked

85 citations

Virginia L. Filiaci, Adrianne Mallen, Kristina W. Thiel, Eric J. Devor, Katherine Moxley +17 more

Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients

Cell(2022)10.1016/j.cell.2022.01.003

N/A

0.973DataRank · unranked

654 citations

Christopher J. Fong, Anisha Luthra, Shaleigh Smith, Renzo G. DiNatale, Subhiksha Nandakumar +70 more

Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-0621

N/A

0.949DataRank · unranked

22 citations

Ignace Vergote, Susana Banerjee, Esther Drill, Elsa Kalbacher, Mansoor Raza Mirza +25 more

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.05.045

N/A

0.920DataRank · unranked

18 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +21 more

Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.06.018

N/A

0.908DataRank · unranked

28 citations

Michael A. Bookman, Jalid Sehouli, Austin Miller, Richard T. Penson, Çağatay Taşkıran +20 more

Ovarian cancer mutational processes drive site-specific immune evasion

Nature(2022)10.1038/s41586-022-05496-1

N/A

0.863DataRank · unranked

314 citations

Florian Uhlitz, Nicholas Ceglia, Jamie Lim, Michelle Wu, Neeman Mohibullah +56 more

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator’s choice of treatment in patients with recurrent low grade serous ovarian cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005919

N/A

0.812DataRank · unranked

25 citations

Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Michel Fabbro, David M. O’Malley +16 more

Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses

Nature Medicine(2024)10.1038/s41591-024-02942-7

N/A

0.790DataRank · unranked

26 citations

Beryl Manning‐Geist, Qin Zhou, Tara E. Soumerai, Aliya Holland, Arnaud Da Cruz Paula +23 more

Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-007929

N/A

0.783DataRank · unranked

19 citations

Matthew H. Taylor, Carol Aghajanian, Allen Lee Cohn, Marcia S. Brose, Christopher Di Simone +12 more

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Journal of Clinical Oncology(2025)10.1200/jco-25-00112

N/A

0.722DataRank · unranked

36 citations

Els Van Nieuwenhuysen, Carol Aghajanian, Véronique D’Hondt, Bradley J. Monk, Andrew R. Clamp +20 more

Clinicopathologic and Genomic Analysis of TP53 -Mutated Endometrial Carcinomas

Clinical Cancer Research(2021)10.1158/1078-0432.ccr-20-4436

N/A

0.705DataRank · unranked

109 citations

Wissam Dahoud, Chad Vanderbilt, Sarah Chiang, Rajmohan Murali, Eric Rios‐Doria +8 more

High-Sensitivity Mutation Analysis of Cell-Free DNA for Disease Monitoring in Endometrial Cancer

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-1134

N/A

0.646DataRank · unranked

73 citations

Pier Selenica, Juber Patel, Michelle Wu, Josip Ninčević, Yulia Lakhman +25 more

Phase I and Randomized Phase II Study of Ruxolitinib With Frontline Neoadjuvant Therapy in Advanced Ovarian Cancer: An NRG Oncology Group Study

Journal of Clinical Oncology(2024)10.1200/jco.23.02076

N/A

0.644DataRank · unranked

20 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-22-0713

N/A

0.641DataRank · unranked

71 citations

Ying L. Liu, Kelly A. Devereaux, Arnaud Da Cruz Paula, Qin Zhou, Weining Ma +18 more

Incidence of pelvic lymph node metastasis using modern FIGO staging and sentinel lymph node mapping with ultrastaging in surgically staged patients with endometrioid and serous endometrial carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.03.025

N/A

0.619DataRank · unranked

61 citations

Silvana Pedra Nobre, Kenya Braxton, Kaled M. Alektiar, Mario M. Leitão, Carol Aghajanian +3 more

Comprehensive assessment of germline pathogenic variant detection in tumor-only sequencing

Annals of Oncology(2022)10.1016/j.annonc.2022.01.006

N/A

0.604DataRank · unranked

55 citations

Fresia Pareja, David N. Brown, Ozge Ceyhan‐Birsoy, Maksym Misyura, Satshil Rana +16 more

Molecular Characterization of Endometrial Carcinomas in Black and White Patients Reveals Disparate Drivers with Therapeutic Implications

Cancer Discovery(2023)10.1158/2159-8290.cd-23-0546

N/A

0.587DataRank · unranked

49 citations

Antonio Marra, Pier Selenica, Eric Rios‐Doria, Amir Momeni Boroujeni, Michael F. Berger +12 more

A phase 2 trial of zanidatamab in HER2-overexpressed advanced endometrial carcinoma and carcinosarcoma (ZW25-IST-2)

Gynecologic Oncology(2024)10.1016/j.ygyno.2023.12.028

N/A

0.583DataRank · unranked

12 citations

M. Herman Chui, Qin Zhou, Alexia Iasonos, Debra Sarasohn, Seth M. Cohen +9 more

Disparities in cancer genetics care by race/ethnicity among pan‐cancer patients with pathogenic germline variants

Cancer(2022)10.1002/cncr.34434

N/A

0.571DataRank · unranked

44 citations

Anna Maio, Yelena Kemel, Erin Salo‐Mullen, Margaret Sheehan, Prince Ray Tejada +22 more

Ongoing genome doubling shapes evolvability and immunity in ovarian cancer

Nature(2025)10.1038/s41586-025-09240-3

N/A

0.553DataRank · unranked

39 citations

Ignacio Vázquez-Garćıa, Matthew Myers, Duaa H. Al-Rawi, Matthew Zatzman, Adam C. Weiner +53 more

Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.02.015

N/A

0.533DataRank · unranked

34 citations

Deborah F. DeLair, Lorenzo Ferrando, Daniel Fix, Robert A. Soslow, Kay J. Park +16 more

A phase I/II study of ruxolitinib with frontline neoadjuvant and post-surgical therapy in patients with advanced epithelial ovarian, Fallopian tube, or primary peritoneal cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.5501

N/A

0.512DataRank · unranked

9 citations

Ronald J. Buckanovich, Michael W. Sill, Robert S. Mannel, Joan L. Walker, Paul DiSilvestro +13 more

Comprehensive analysis of germline drivers in endometrial cancer

JNCI Journal of the National Cancer Institute(2023)10.1093/jnci/djad016

N/A

0.470DataRank · unranked

22 citations

Eric Rios‐Doria, Karen A. Cadoo, Amanda Catchings, Anna Maio, Yelena Kemel +37 more

Assessing the Genomic Landscape of Cervical Cancers: Clinical Opportunities and Therapeutic Targets

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-1078

N/A

0.464DataRank · unranked

21 citations

Vignesh Ravichandran, Kathryn Miller, Chad Vanderbilt, Qin Zhou, Alexia Iasonos +17 more

Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.06.008

N/A

0.457DataRank · unranked

20 citations

Mackenzie W. Sullivan, Qin Zhou, Alexia Iasonos, Pier Selenica, Chrystal Stallworth +9 more

Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission

Cancers(2023)10.3390/cancers15051458

N/A

0.457DataRank · unranked

20 citations

Sacha Gnjatic, Carol Aghajanian, Jason Konner, Sarah H. Kim, Debra Sarasohn +12 more

Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survival

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.11.019

N/A

0.449DataRank · unranked

19 citations

Pier Selenica, Thomas Boerner, Kara Long Roche, Yonghong Xiao, Tiffany Sia +23 more

A phase II study of MK-2206, an AKT inhibitor, in uterine serous carcinoma

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.100974

N/A

0.416DataRank · unranked

15 citations

Niya Xiong, Andrea P. Myers, Nabihah Tayob, Victoria Engvold, Madeline Polak +14 more

Ongoing genome doubling promotes evolvability and immune dysregulation in ovarian cancer

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.07.11.602772

N/A

0.415DataRank · unranked

11 citations

Ignacio Vázquez-Garćıa, Matthew Myers, Matthew Zatzman, Duaa H. Al-Rawi, Adam C. Weiner +52 more

Pathogenic germline variants in patients with endometrial cancer of diverse ancestry

Cancer(2023)10.1002/cncr.35071

N/A

0.406DataRank · unranked

14 citations

Sushmita Gordhandas, Kanika Arora, Eric Rios‐Doria, Karen A. Cadoo, Amanda Catchings +26 more

Incorporation of triapine (T) with cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5502

N/A

0.396DataRank · unranked

13 citations

Wei Deng, Loren K. Mell, Debra L. Richardson, Joan L. Walker, Laura L. Holman +15 more

Phase II study of enzalutamide in androgen receptor positive, recurrent, high- and low-grade serous ovarian cancer

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.10.087

N/A

0.385DataRank · unranked

12 citations

Sushmita Gordhandas, Dilip D. Giri, Alexia Iasonos, Qin Zhou, Jeffrey Girshman +12 more

Pattern of disease and response to pembrolizumab in recurrent cervical cancer

Gynecologic Oncology Reports(2021)10.1016/j.gore.2021.100831

N/A

0.345DataRank · unranked

9 citations

Olga T. Filippova, Sara A. Hayes, Nadeem R. Abu‐Rustum, Carol Aghajanian, Vance Broach +14 more

Diagnosis and management of an endometrial cancer patient with Cowden syndrome

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.08.008

N/A

0.345DataRank · unranked

9 citations

Sónia Gatius, Ying Liu, Mabel Gil, Arnaud Da Cruz Paula, Noemí Tuset +5 more

Germline drivers of gynecologic carcinosarcomas

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.04.024

N/A

0.330DataRank · unranked

8 citations

Sushmita Gordhandas, Ozge Ceyhan‐Birsoy, Yelena Kemel, Anna Maio, Erin Salo‐Mullen +22 more

Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer

Cancer(2024)10.1002/cncr.35523

N/A

0.330DataRank · unranked

8 citations

Stephen Graves, Anusha Adkoli, Qin Zhou, Alexia Iasonos, Lora H. Ellenson +8 more

Tracking clonal evolution of drug resistance in ovarian cancer patients by exploiting structural variants in cfDNA

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.08.21.609031

N/A

0.312DataRank · unranked

7 citations

Ignacio Vázquez-Garćıa, Grittney Tam, Michelle Wu, Nancy Varice, Eliyahu Havasov +22 more

Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.005

N/A

0.312DataRank · unranked

7 citations

Tiffany Sia, Christopher J. Fong, Aliya Khurram, Michele Waters, Yelena Kemel +19 more

The genomic landscape of distant metastatic endometrial cancer

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.006

N/A

0.292DataRank · unranked

6 citations

Subhiksha Nandakumar, Elizabeth Kertowidjojo, Bastien Nguyen, Lea A. Moukarzel, Arnaud Da Cruz Paula +12 more

Controversies in the Management of Mesonephric and Mesonephric-Like Adenocarcinomas of the Female Genital Tract

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2025.101638

N/A

0.276DataRank · unranked

4 citations

Kay J. Park, Simran Makker, Jeffrey Girshman, Carol Aghajanian, Rachel N. Grisham +1 more

Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.06.026

N/A

0.269DataRank · unranked

5 citations

Lindsey Finch, Alexia Iasonos, Qin Zhou, Jeffrey Girshman, Rashmi Chhetri-Long +14 more

A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.06.021

N/A

0.241DataRank · unranked

4 citations

Austin Miller, Robert A. Soslow, Heather A. Lankes, Deborah F. DeLair, Sheila Segura +10 more

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer

medRxiv(2024)10.1101/2024.06.07.24308618

N/A

0.104DataRank · unranked

1 citations

Eduardo Ortiz, Caroline S. Jiang, Christian Dagher, Carlo Sevilla, Jeffrey Girshman +10 more

Carboplatin dosing in the treatment of ovarian cancer: An NRG oncology group study

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.05.013

N/A

0.104DataRank · unranked

1 citations

Austin Miller, Judith A. Smith, Stuart M. Lichtman, Michael A. Bookman, Carol Aghajanian +17 more

Whole-genome sequencing-based characterization of endometrial serous carcinoma

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.08.022

N/A

0DataRank · unranked

0 citations

D. N. Brown, Arnaud Da Cruz Paula, Carol Aghajanian, Nadeem R Abu-Rustum, Lora H. Ellenson +2 more

Mutant FOXL2C134W Hijacks SMAD4 and SMAD2/3 to Drive Adult Granulosa Cell Tumors

Cancer Research(2020)10.1158/0008-5472.can-20-0259

N/A

0DataRank · unranked

57 citations

Mads Lerdrup, Daniela Kleine‐Kohlbrecher, Faizaan Mohammad, Simone Sidoli, Ole N. Jensen +14 more

A phase I open-label study of selinexor with paclitaxel and carboplatin in patients with advanced ovarian or endometrial cancers

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.10.019

N/A

0DataRank · unranked

16 citations

Rachel N. Grisham, Karen A. Cadoo, Chrisann Kyi, William P. Tew, Claire F. Friedman +14 more

Results of an abbreviated phase II study of AKT inhibitor MK-2206 in the treatment of recurrent platinum-resistant high grade serous ovarian, fallopian tube, or primary peritoneal carcinoma (NCT 01283035)

Gynecologic Oncology Reports(2020)10.1016/j.gore.2020.100546

N/A

0DataRank · unranked

18 citations

Zhenying Tan‐Wasielewski, Carol Aghajanian, Robert L. Coleman, Jennifer Curtis, Michelle S. Hirsch +6 more

Impact of Provider Imaging Practices on Survival Outcomes in Advanced Ovarian Cancer

Journal of the National Comprehensive Cancer Network(2020)10.6004/jnccn.2019.7376

N/A

0DataRank · unranked

5 citations

Deborah Korenstein, Carol Aghajanian, Brooke Barrow, Michael Curry, Roisin E. O’Cearbhaill +1 more

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

International Journal of Gynecological Cancer(2021)10.1136/ijgc-2020-002240

N/A

0DataRank · unranked

15 citations

Domenica Lorusso, Amit M. Oza, Carol Aghajanian, Ana Oaknin, Andrew Dean +18 more

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

Cancer Medicine(2021)10.1002/cam4.4260

N/A

0DataRank · unranked

6 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Andrew Dean, Nicoletta Colombo +19 more

Outcomes of incidentally detected ovarian cancers diagnosed at time of risk-reducing salpingo-oophorectomy in BRCA mutation carriers

Gynecologic Oncology(2021)10.1016/j.ygyno.2021.02.006

N/A

0DataRank · unranked

5 citations

Silvana Pedra Nobre, Nisha Pradhan, Maya Yasukawa, Qin Zhou, Alexia Iasonos +11 more

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.08.021

N/A

0DataRank · unranked

57 citations

Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean +17 more

Gastric-type adenocarcinoma of the cervix: Clinical outcomes and genomic drivers

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.10.003

N/A

0DataRank · unranked

48 citations

Dib Sassine, Alli Straubhar, Aaron Praiss, Carol Aghajanian, Kaled M. Alektiar +17 more

Pre-clinical activity of the oral DNA-PK inhibitor, peposertib (M3814), combined with radiation in xenograft models of cervical cancer

Scientific Reports(2022)10.1038/s41598-021-04618-5

N/A

0DataRank · unranked

33 citations

Beryl Manning‐Geist, Christina Henson, Gopa Iyer, Ginger J. Gardner, Yukio Sonoda +5 more

Durvalumab with or without tremelimumab in patients with persistent or recurrent endometrial cancer or endometrial carcinosarcoma: A randomized open-label phase 2 study

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.028

N/A

0DataRank · unranked

23 citations

Eric Rios Doria, Jason Konner, Stuart M. Lichtman, Qin Zhou, Alexia Iasonos +18 more

Hyperthermic intraperitoneal chemotherapy (HIPEC) with carboplatin induces distinct transcriptomic changes in ovarian tumor and normal tissues

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.02.022

N/A

0DataRank · unranked

15 citations

Lorenzo Ferrando, Higinio Dopeso, Anthe A. Stylianou, Thais Basili, Fresia Pareja +14 more

Small cell neuroendocrine carcinoma of the cervix: Analysis of prognostic factors and patterns of metastasis

Gynecologic Oncology Reports(2022)10.1016/j.gore.2022.101058

N/A

0DataRank · unranked

11 citations

Brooke A. Schlappe, Qin Zhou, Alexia Iasonos, Mario M. Leitão, Kay J. Park +8 more

Management of patients with early-stage ovarian clear cell carcinoma: risk stratification and fertility conservation

International Journal of Gynecological Cancer(2022)10.1136/ijgc-2022-003935

N/A

0DataRank · unranked

10 citations

Sushmita Gordhandas, Anjelica Hodgson, Qin Zhou, Alexia Iasonos, S. Dennis +12 more

SWOG 1815: A phase III randomized trial of gemcitabine, cisplatin, and nab-paclitaxel versus gemcitabine and cisplatin in newly diagnosed, advanced biliary tract cancers.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.lba490

N/A

0DataRank · unranked

99 citations

Katherine A. Guthrie, Aaron J. Scott, Mitesh J. Borad, Laura W. Goff, Khalid Matin +15 more

Integration of clinical sequencing and immunohistochemistry for the molecular classification of endometrial carcinoma

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.05.059

N/A

0DataRank · unranked

89 citations

Amir Momeni Boroujeni, Claire F. Friedman, Pier Selenica, Qin Zhou, Michelle Wu +16 more

Adverse events and oncologic outcomes with combination lenvatinib and pembrolizumab for the treatment of recurrent endometrial cancer

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.09.010

N/A

0DataRank · unranked

19 citations

Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann +8 more

Chemotherapy response in low‐grade serous ovarian carcinoma at a comprehensive cancer center: Readdressing the roles of platinum and cytotoxic therapies

Cancer(2023)10.1002/cncr.34753

N/A

0DataRank · unranked

19 citations

Ryan Kahn, David Nemirovsky, Jeffrey Girshman, Anya Laibangyang, Sushmita Gordhandas +8 more

Landscape of chromatin remodeling gene alterations in endometrial carcinoma

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.010

N/A

0DataRank · unranked

12 citations

Chad Vanderbilt, Elham Yousefi, Nadeem R. Abu‐Rustum, Carol Aghajanian, Robert A. Soslow +4 more

TERT promoter mutations and gene amplification in endometrial cancer

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.10.007

N/A

0DataRank · unranked

12 citations

Antonio Marra, Qin Zhou, Eric Rios‐Doria, Amir Momeni Boroujeni, Alexia Iasonos +7 more

Predicting outcomes in female germ cell tumors using a modified International Germ Cell Cancer Collaborative Group classification system to guide management

Gynecologic Oncology(2023)10.1016/j.ygyno.2022.12.022

N/A

0DataRank · unranked

11 citations

Beryl Manning‐Geist, Andrea Knežević, Luxue Deng, Maria Bromberg, Samuel A. Funt +13 more

Data from Microsatellite Instability–High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical Profiles

(2023)10.1158/1078-0432.c.6532995.v1

N/A

0DataRank · unranked

0 citations

Ying L. Liu, Kelly A. Devereaux, Arnaud Da Cruz Paula, Qin Zhou, Weining Ma +18 more

Germline variants in non-BRCA1/2 homologous recombination-related genes and ovarian cancer: Analysis of tumor phenotype and survival.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5565

N/A

0DataRank · unranked

0 citations

Pier Selenica, Thomas Boerner, Yonghong Xiao, Tiffany Sia, Margaret Sheehan +15 more

Pathogenic germline variants in patients with endometrial cancer across diverse ancestries.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.5596

N/A

0DataRank · unranked

0 citations

Sushmita Gordhandas, Kanika Arora, Anna Maio, Yelena Kemel, Margaret Sheehan +15 more

Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.03.027

N/A

0DataRank · unranked

20 citations

Danielle Enserro, Matthew S. Block, Steven Waggoner, Linda Duska, Andrea E. Wahner-Hendrickson +11 more

Body mass index and adiposity influence responses to immune checkpoint inhibition in endometrial cancer

Journal of Clinical Investigation(2024)10.1172/jci180516

N/A

0DataRank · unranked

19 citations

Eduardo Ortiz, Caroline S. Jiang, Christian Dagher, Carlo Sevilla, Jeffrey Girshman +10 more

A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor–Positive Advanced or Recurrent Endometrial Cancer

Clinical Cancer Research(2024)10.1158/1078-0432.ccr-24-1999

N/A

0DataRank · unranked

16 citations

Qin Zhou, Alexia Iasonos, William A. Zammarrelli, Britta Weigelt, Lora H. Ellenson +17 more

Mesonephric and mesonephric-like adenocarcinomas of gynecologic origin: A single-center experience with molecular characterization, treatment, and oncologic outcomes

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.01.015

N/A

0DataRank · unranked

17 citations

Charlie White, Alexia Iasonos, Pier Selenica, Oliver Zivanovic, S. Dennis +7 more

Prognosis of isolated tumor cells and use of molecular classification in early stage endometrioid endometrial cancer

International Journal of Gynecological Cancer(2024)10.1136/ijgc-2024-005522

N/A

0DataRank · unranked

9 citations

Nadeem R. Abu‐Rustum, Kaled M. Alektiar, Vicky Makker, Ying L. Liu, Dmitriy Zamarin +8 more

Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.11.011

N/A

0DataRank · unranked

3 citations

Mackenzie W. Sullivan, Anusha Adkoli, Qin Zhou, Alexia Iasonos, Pier Selenica +10 more

Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.12.009

N/A

0DataRank · unranked

2 citations

Aaron Praiss, Sarah Chiang, Kelly A. Devereaux, James Huang, Gabrielle Rizzuto +6 more

Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile

Gynecologic Oncology(2024)10.1016/j.ygyno.2024.10.029

N/A

0DataRank · unranked

1 citations

Yulia Lakhman, Carol Aghajanian, Nadeem R. Abu‐Rustum, Lora H. Ellenson, Britta Weigelt +2 more

ERBB2 mutations define a subgroup of endometrial carcinomas associated with high tumor mutational burden and the microsatellite instability‐high ( MSI ‐H) molecular subtype

Molecular Oncology(2024)10.1002/1878-0261.13698

N/A

0DataRank · unranked

2 citations

Pier Selenica, Weining Ma, Sara Moufarrij, Christian Dagher, Thais Basili +8 more

Neoadjuvant or concurrent atezolizumab with chemoradiation for locally advanced cervical cancer: a randomized phase I trial

Nature Communications(2025)10.1038/s41467-024-55200-2

N/A

0DataRank · unranked

18 citations

Dmitriy Zamarin, Wei Deng, Heather A. Lankes, Giulio Pesci, Hayeon Kim +19 more

Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.05.015

N/A

0DataRank · unranked

9 citations

Qin Zhou, Carol Aghajanian, Nadeem R. Abu‐Rustum, Jennifer J. Mueller, Lora H. Ellenson +5 more

A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.003

N/A

0DataRank · unranked

9 citations

Michael W. Sill, Paola A. Gehrig, Jason D. Merker, David L. Corcoran, Adam D. Pfefferle +15 more

TROP2 expression and therapeutic targeting in uterine carcinosarcoma

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.04.590

N/A

0DataRank · unranked

6 citations

Higinio Dopeso, David N. Brown, Hunter Green, Kaitlyn Gill, Julia Tengelin +16 more

Basket study of oral progesterone antagonist onapristone extended-release in combination with anastrozole in progesterone receptor-positive recurrent adult-type granulosa cell tumor of the ovary

International Journal of Gynecological Cancer(2025)10.1016/j.ijgc.2024.100005

N/A

0DataRank · unranked

3 citations

Sarah Andres, Alexia Iasonos, Qin Zhou, Jeffrey Girshman, Rashmi Chhetri-Long +15 more

Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody–drug conjugate

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.03.023

N/A

0DataRank · unranked

2 citations

Matthew Flint, M. Herman Chui, Jason Konner, Claire F. Friedman, Angela K. Green +14 more

Image guided brachytherapy quality assurance on NRG GY017 investigating immunotherapy in addition to chemoradiation for locally advanced cervical cancer

Brachytherapy(2025)10.1016/j.brachy.2025.09.011

N/A

0DataRank · unranked

2 citations

Wei Deng, Dmitriy Zamarin, Ying Xiao, Junzo Chino, Stanley Benedict +18 more

Germline landscape of high grade serous ovarian cancer across age groups: Is age just a number?

Gynecologic Oncology(2025)10.1016/j.ygyno.2025.08.016

N/A

0DataRank · unranked

1 citations

Sara Moufarrij, Juliet Milani, Sarah Kane, Qin Zhou, Christopher J. Fong +20 more